Literature DB >> 16877147

Influence of hemoglobin levels on inpatient rehabilitation outcomes after total knee arthroplasty.

Paul T Diamond1, Mark R Conaway, Samir H Mody, Kiran Bhirangi.   

Abstract

This retrospective study examined the influence of hemoglobin (Hb) on the outcomes of 184 acute inpatient rehabilitation patients admitted to a single university-based inpatient rehabilitation facility after primary total knee arthroplasty between 2001 and 2003. Patient function was measured using the Functional Independence Measure (FIM) instrument. Average length of stay was 9.4 days. Total FIM score increased from 81.5 to 110.8. Mean baseline Hb was 10.5 g/dL. Multivariate analyses demonstrated that a higher Hb at baseline was associated with significantly shorter length of stay (P = .004) and greater FIM efficiency (change in total FIM score/length of stay) (P = .04). Hemoglobin is associated with rehabilitation outcomes after total knee arthroplasty; additional research into the influence of blood management strategies on rehabilitation outcomes is warranted.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16877147     DOI: 10.1016/j.arth.2005.09.006

Source DB:  PubMed          Journal:  J Arthroplasty        ISSN: 0883-5403            Impact factor:   4.757


  16 in total

1.  The comparative efficacies of intra-articular and IV tranexamic acid for reducing blood loss during total knee arthroplasty.

Authors:  Jai-Gon Seo; Young-Wan Moon; Sang-Hoon Park; Sang-Min Kim; Kyung-Rae Ko
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2012-06-24       Impact factor: 4.342

2.  Autologous re-transfusion drain compared with no drain in total knee arthroplasty: a randomised controlled trial.

Authors:  Wieger Horstmann; Bart Kuipers; David Ohanis; Robert Slappendel; Boudewijn Kollen; Cees Verheyen
Journal:  Blood Transfus       Date:  2013-07-26       Impact factor: 3.443

3.  Platelet-rich plasma prevents blood loss and pain and enhances early functional outcome after total knee arthroplasty: a prospective randomised controlled study.

Authors:  Aditya K Aggarwal; V S Shashikanth; Neelam Marwaha
Journal:  Int Orthop       Date:  2013-10-11       Impact factor: 3.075

4.  Topical tranexamic acid reduces blood loss and transfusion rates associated with primary total hip arthroplasty.

Authors:  Chih-Hsiang Chang; Yuhan Chang; Dave W Chen; Steve W N Ueng; Mel S Lee
Journal:  Clin Orthop Relat Res       Date:  2014-01-03       Impact factor: 4.176

5.  The use of patient-specific instruments does not reduce blood loss during minimally invasive total knee arthroplasty?

Authors:  Emmanuel Thienpont; Irina Grosu; Frederic Paternostre; Pierre-Emmanuel Schwab; Jean Cyr Yombi
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2014-03-27       Impact factor: 4.342

6.  Use of patient-specific cutting blocks reduces blood loss after total knee arthroplasty.

Authors:  Vicente J León; María A Lengua; Víctor Calvo; Alonso J Lisón
Journal:  Eur J Orthop Surg Traumatol       Date:  2016-12-20

7.  Structural equation model analysis of the length-of-hospital stay after lumbar spine surgery.

Authors:  Saddam F Kanaan; Lemuel R Waitman; Hung-Wen Yeh; Paul M Arnold; Douglas C Burton; Neena K Sharma
Journal:  Spine J       Date:  2014-11-13       Impact factor: 4.166

8.  [Analgaesia, anaesthesia, and rehabilitation for minimally invasive total knee arthroplasty].

Authors:  M Pietsch; S Hofmann
Journal:  Orthopade       Date:  2007-12       Impact factor: 1.087

9.  [Konzept Perioperative management for endoprosthetic hip joint replacement. The functional interdisciplinary therapy (FIT) concept].

Authors:  J Jerosch; J Heisel
Journal:  Unfallchirurg       Date:  2010-01       Impact factor: 1.000

10.  Low Dose Perioperative Intravenous Tranexamic Acid in Patients Undergoing Total Knee Arthroplasty: A Double-Blind Randomized Placebo Controlled Clinical Trial.

Authors:  Mahdi Motififard; Mohammad Ali Tahririan; Mehdi Saneie; Sajad Badiei; Amin Nemati
Journal:  J Blood Transfus       Date:  2015-12-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.